Caris Life Sciences (CAI) Total Debt (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Total Debt of $381.2 million for Q1 2026, up 0.59% quarter-over-quarter from $379.0 million in Q4 2025.

Caris Life Sciences (CAI) Total Debt (2024 - 2026) Analysis & Trends

Caris Life Sciences' Total Debt history runs 3 years deep, the most recent figure standing at $381.2 million for Q1 2026.

In Q1 2026, Total Debt changed N/A year-over-year to $381.2 million; the TTM figure through Mar 2026 stood at $381.2 million (changed N/A YoY), while the FY2025 annual figure was $379.0 million, down 12.52% from the prior year.
Total Debt for Q1 2026 stood at $381.2 million, up from $379.0 million in the prior quarter.
The five-year high for Total Debt was $433.2 million in Q4 2024, with the low at $373.5 million in Q2 2025.
The 3-year median for Total Debt is $379.0 million (2025), against an average of $388.6 million.
Peak annual rise in Total Debt reached 12.52% in 2025, while the deepest fall reached 12.52% in 2025.
Caris Life Sciences' Total Debt stood at $433.2 million in 2024, then retreated by 12.52% to $379.0 million in 2025, then advanced by 0.59% to $381.2 million in 2026.
Business Quant data shows CAI's Total Debt at $381.2 million in Q1 2026, $379.0 million in Q4 2025, and $376.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	393.15 Mn

Download Data